Legal Digest: Patent Disputes in Life Sciences (September 2026)
On 23 April 2026, the Council of the EU adopted its 20th package of restrictive measures against Russia – a landmark decision that, for the first time, introduces dedicated sanctions mechanisms targeting the realm of intellectual property.
From 1 September 2026, new rules for calculating remuneration for employees who are the authors of employee inventions, utility models and industrial designs will come into force. The document fundamentally changes the approach to such payments.
India has long and firmly established itself as the ‘pharmacy of the world’, as the country produces a fifth of all generics and provides affordable medicines to millions of people across the globe. However, India is now transitioning from copying innovative molecules to creating them. Amid the restructuring of global supply chains and strategic rapprochement with Russia, India is becoming both a battleground for fierce patent wars and a unique laboratory for joint research. How can Russian pharmaceutical companies establish intellectual property protection in a jurisdiction where the balance between the interests of pharmaceutical giants and the affordability of medicines for the population is enshrined in law? Boris Malakhov and Natalya Thotahewage analyse the key features of patenting and the prospects for technological alliances between Moscow and Delhi.
The past days have been marked by landmark rulings from the Russian Supreme and Constitutional Courts, decisions that will influence future case law and the pharmaceutical market as a whole.
We are delighted to announce that Lidings has updated The Pharma Legal Handbook: Russia - practical directory focused on the key aspects of legislative regulation of pharmaceutical industry in Russia.
Lidings experts have authored the The Pharma Legal Handbook — practical directory focused on the key aspects of legislative regulation of pharmaceutical industry in Russia. The Handbook covers major issues linked to regulation, pricing, clinical and preclinical trials, marketing, manufacturing, trademarks and patents in Russia and is a must-have for any company operating in the country or looking to enter the market.
On 15 February 2024, the President of the Russian Federation signed Decree No. 122 “On Improving the Procedure for Decision-Making on the Use of Inventions, Utility Models and Industrial Designs to Ensure the Economic Security of the Russian Federation” (“Decree”), which requires the Russian Government to form a Sub-commission on the use of inventions, utility models and industrial designs (“Sub-Commission”). The Sub-Commission will be formed under the Government Commission on Economic Development and Integration.
The site uses cookie technology to ensure optimal performance, analyze usage and improve user experience. By continuing to use the site, you consent to the placement of cookies on your device on the terms set out in the Privacy Policy.
To ensure optimal performance, analyze usage and improve user experience, the website may use web analytics systems (including Yandex.Metrica), which may place cookies on your device.
By continuing to use the website, you agree to the use of these technologies and the placement of cookies. You can delete cookies from your device through your browser settings and you can block the placement of cookies, however, in doing so, some website features may not be available due to the engine's technological limitations.
You can find more information in the Privacy Policy.